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Receptor heteromerization has the potential to alter every facet of receptor functioning,
leading to new pharmacological proﬁles with increased signaling diversity and regulation
from that of the monomeric receptor, or indeed receptor homomer. An understanding
of the molecular consequences of receptor heteromerization will provide new insights
into the physiology and pathology mediated by receptors, expanding the possibilities for
pharmacological discovery. Particularly advantageous approaches to investigate novel het-
eromer pharmacology utilize cell-based assay technologies that assess ligand-dependent
functional responses speciﬁc to the receptor heteromer. Importantly, this allows for dif-
ferentiation of heteromer-speciﬁc pharmacology from pharmacology associated with the
co-expressed receptor monomers and homomers. The Receptor-Heteromer Investigation
Technology (Receptor-HIT) successfully employs a proximity-based reporter system, such
as bioluminescence resonance energy transfer (BRET), in a conﬁguration that enables deter-
mination of such heteromer-speciﬁc pharmacology. Therefore, Receptor-HIT provides a
simple, robust and versatile approach for investigating the elusive “biochemical ﬁngerprint”
of receptor heteromers.
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INTRODUCTION
There are many types of membrane receptors that can be broadly
classiﬁed into three families based on distinct mechanisms of sig-
nal transduction, namely G protein-coupled receptors (GPCRs),
receptor tyrosine kinases (RTKs), and ionotropic receptors, which
are channels that directly allow ﬂux of ions upon activation. Addi-
tionally, there are intracellular receptors such as those binding
steroids. It is well established that many of these receptors exist
as oligomeric species consisting of two or more receptor subunits
(Neubig et al., 2003). In many cases, dimerization or oligomer-
ization is required for the formation of a functional receptor
unit. These receptors are known as “homomeric receptors” if
the constituents are the same and “heteromeric receptors” if the
constituents differ (Ferré et al., 2009). RTKs are the archetypal
homomeric and heteromeric receptors, as they require homo-
or heteromerization for activation and signaling (Lemmon and
Schlessinger, 2010). For GPCRs, classic examples of heteromeric
receptors are the GABAB receptor (GABABR1-GABABR2; Jones
et al., 1998; Kaupmann et al., 1998; White et al., 1998) and taste
receptors (T1R-T2R and T2R-T3R; Nelson et al., 2001, 2002;
Li et al., 2002). In contrast, “receptor homomers” and “recep-
tor heteromers” are macromolecular complexes that include two
or more functional receptor units (identical or different, respec-
tively) and display pharmacology that is distinct from that of their
component receptors (Ferré et al., 2009). The concepts of GPCR
homomerization and heteromerization have been described for
30 years (Fuxe et al., 2010), but have only recently become widely
accepted. Furthermore, it is now clear that an array of receptor
homomers and heteromers from all classes of membrane recep-
tors exist (Liu et al., 2000, 2006; Maudsley et al., 2000; Lee et al.,
2002; Nair and Sealfon, 2003; Olivares-Reyes et al., 2005; Watt
et al., 2009). As both receptor homomers and receptor heteromers
have the potential to attain a unique pharmacological proﬁle, their
existence adds another level of complexity to cell signaling sys-
tems. Of the two classes, receptor heteromers have been the major
focus of research interest due to the numerous potential receptor
combinations, aswell as the difﬁculty in separating the pharmacol-
ogy of a monomer from its homomer. The unique pharmacology
associatedwith receptor heteromers has been termed its“biochem-
ical ﬁngerprint” (Ferré et al., 2009) and provides a mechanism
for achieving greater signaling diversity and speciﬁcity. Receptor
heteromers are therefore viewed as a new class of drug target,
providing the opportunity for designing heteromer-speciﬁc/-
biased drugs with improved selectivity and reduced side effects
(Mustafa et al., 2010).
Investigating the pharmacological properties of receptor het-
eromers can be a particularly difﬁcult process as the heteromer-
speciﬁc pharmacology needs to be differentiated from pharma-
cology of associated monomers/homomers. Due to difﬁculties in
investigating heteromers in native tissue, heterologous expression
systems currently provide the major method to study heteromers.
The ﬁrst step is the identiﬁcation of a heteromer, and subse-
quent characterization of its biochemical ﬁngerprint. In time, this
biochemical ﬁngerprint will ideally be used to demonstrate the
presence of the heteromer in native tissue. To achieve this end,
it is critical that the initial cell-based assays employed are able to
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robustly differentiate heteromer-speciﬁc pharmacology from that
of the component receptors.
RECEPTOR-HETEROMER INVESTIGATION TECHNOLOGY
A novel technique recently developed to enable identiﬁcation
and pharmacological proﬁling of heteromers is the Receptor-
Heteromer Investigation Technology (Receptor-HIT). This pro-
vides information on ligand-dependent functional responses
speciﬁc to the heteromer. Receptor-HIT uses a proximity-
based reporter system comprising four elements, three of which
are: labeled Receptor A, untagged Receptor B, and a labeled
interacting Protein C that is recruited to the heteromer in a
ligand-dependent manner (See et al., 2011). This conﬁguration is
illustrated in Figure 1 using bioluminescence resonance energy
transfer (BRET), however, the approach can be applied using
a variety of reporter systems including ﬂuorescence resonance
energy transfer (FRET), bimolecular ﬂuorescence complementa-
tion (BiFC), bimolecular luminescence complementation (BiLC),
enzyme fragment complementation (EFC), and the protease-
cleaved transcription factor assay system known as TangoTM
(Mustafa et al., 2010; Mustafa and Pﬂeger, 2011). Co-expression of
the aforementioned elements in cells enables the signal between the
label of choice on Receptor A and complementary label on Protein
C to be monitored. The fourth element in the system is a ligand
that, upon binding to untaggedReceptor B or the heteromer, selec-
tivelymodulates the recruitment of ProteinC toReceptor B and/or
the heteromer (See et al., 2011; Mustafa et al., 2012). Receptor-HIT
is unsuitable for investigating homomers due to this receptor-
selectivity requirement, but heteromers of closely related receptor
subtypes where a selective agonist may be unavailable can still be
assessed. This issue is overcome by additional use of an antag-
onist selective for Receptor A, thereby meaning that Receptor B
FIGURE 1 | Utilization of Receptor-HIT on the BRET platform to
investigate receptor heteromerization. BRET is a biophysical phenomenon
involving the non-radiative transfer of energy from a donor enzyme to an
acceptor ﬂuorophore. The donor enzyme is a variant of Renilla luciferase
(Rluc), and energy emission results from the oxidation of its substrate
coelenterazine h to coelenteramide (Pﬂeger and Eidne, 2006; Pﬂeger et al.,
2006). If the acceptor ﬂuorophore (such as yellow ﬂuorescent protein; YFP) is
correctly orientated and within 10 nm, it will be excited by the energy
transferred from the donor resulting in the emission of light at a characteristic
wavelength (Dacres et al., 2010). BRET is used to study protein-protein
interactions through tagging one of the proteins of interest with the donor
enzyme and the other protein with the acceptor ﬂuorophore (Pﬂeger and
Eidne, 2006). If the two proteins are in close proximity, the energy generated
by the donor enzyme will be transferred to the acceptor ﬂuorophore. The
resulting BRET signal provides evidence for the two fusion proteins being in
the same complex. In contrast to BRET between Rluc andYFP fused to each
receptor, a speciﬁc receptor heteromer can be monitored by ligand-induced
BRET due to proximity of a tagged receptor and a tagged intracellular protein
used as a reporter partner (such as β-arrestin or G protein). In this system,
energy transfer is measured between Receptor A-Rluc and a Protein C-YFP
that interacts with the heteromer complex after selective activation of
Receptor B or the heteromer itself. In addition to the induction of BRET by the
Receptor B or heteromer-selective ligand providing evidence for Receptor AB
heteromerization, it also identiﬁes a biological function of the heteromer.
Reprinted from Ayoub and Pﬂeger (2010). Copyright © 2010, with permission
from Elsevier.
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and/or the heteromer are still activated selectively. Alternatively,
it is possible to use a non-selective ligand if it does not modulate
recruitment of Protein C to Receptor A in the absence of Receptor
B (Porrello et al., 2011). Whichever approach is used, generation
of a signal upon application of the ligand indicates that Protein
C has been recruited to the heteromer, thereby bringing the label
on Receptor A into close proximity with the label on Protein C.
The signal obtained is not only indicative of the receptors being
in a heteromeric complex, it also reveals an aspect of the het-
eromer’s pharmacology through generation of ligand-dependent
functional responses.
Receptor-HIT is an excellent assay for identifying and proﬁl-
ing heteromers as signals do not result from the homomeric or
monomeric receptor populations (See et al., 2011). The ligand-
dependent nature of the signal also enables screening, identiﬁca-
tion, and proﬁling of compounds exhibiting heteromer-speciﬁc or
biased signaling (Mustafa and Pﬂeger, 2011; Mustafa et al., 2012).
TheReceptor-HIT assay has largely been publishedwith respect
toGPCRs in the formof theGPCR-Heteromer IdentiﬁcationTech-
nology (GPCR-HIT; Ayoub and Pﬂeger, 2010; Mustafa et al., 2010,
2012; Mustafa and Pﬂeger, 2011; Porrello et al., 2011; See et al.,
2011), however it can also be applied to other receptors, including
RTKs (Pﬂeger, 2011; Story et al., 2011), ionotropic receptors and
steroid receptors. Consequently, there is also an extensive number
of interacting partners that can be used. For example, GPCR-
HIT studies can utilize G proteins or β-arrestins, whereas we have
found Grb2 to be particularly amenable to Receptor-HIT assays
investigating RTKs (Pﬂeger, 2011; Story et al., 2011).
BRET is our preferred platform for Receptor-HIT (Figure 1)
because it can monitor protein proximity in live cells in real time
at 37◦C without the need for cell lysis, the assay does not rely upon
proteins refolding in a complementation event to produce a read-
out, and no alteration of receptor function is required (Mustafa
et al., 2010). The traditional conﬁguration for studying recep-
tor heteromers using BRET involves tagging one receptor with
the Rluc enzyme, while the second receptor is tagged with the
acceptor ﬂuorophore. A particular limitation to this approach
is that overcrowding of receptors in the endoplasmic reticulum
or degradative compartments can lead to non-speciﬁc “bystander
BRET” (Pﬂeger and Eidne, 2006). This is commonly addressed by
employing BRET saturation assays (Mercier et al., 2002), however
these are rather laborious. The ligand dependency of Receptor-
HIT addresses this issue as it requires Receptor B or the heteromer
to be capable of binding ligand (Figure 1), either because it is
sufﬁciently mature and/or because it is appropriately localized
to provide the ligand access for binding. Furthermore, although
providing evidence of proximity of the two receptors, no func-
tional information about the heteromer is revealed by saturation
assays (Mustafa et al., 2012). In contrast, the use of an interact-
ing protein also enables functional responses to be assessed, with
the potential to uncover novel heteromer-speciﬁc pharmacology
(Mustafa et al., 2012).
While there are advantages to using BRET as outlined above,
there are also advantages to using other platforms in certain sit-
uations. For example, although EFC is not a real-time assay
and requires cell lysis for signal detection, it is probably capa-
ble of achieving higher levels of screening throughput than
BRET. Furthermore, assay systems like FRET and BiFC are more
amenable to assessing subcellular localization if combined with
confocal microscopy. However, because FRET uses a ﬂuorophore
as donor, there are issues arising from the need for external
excitation. These include autoﬂuorescence, photobleaching, cell
damage, and direct acceptor excitation. Some of these issues can
be addressed using time-resolved FRET (TR-FRET; Cottet et al.,
2012). BiFC enables speciﬁc visualization of complemented ﬂuo-
rophores, and therefore the fused proteins of interest, but this is
not a real-time assay due to a time delay while refolding occurs
and once complemented, the proteins remain associated (Porrello
et al., 2011). BRET is very sensitive to distance and relative donor–
acceptor orientation. This is advantageous in terms of proximity
speciﬁcity, however, it means that receptors could potentially form
a heteromer without this being detected by BRET, and a lack of
signal should be interpreted with caution (Pﬂeger et al., 2006).
Other platforms may have a lower false-negative rate than BRET,
however, the potential for higher false-positives may then need to
be considered.
APPLICATION OF RECEPTOR-HIT USING BRET
Receptor-HIT has been used effectively on the BRET platform to
investigate multiple established and novel heteromers. The CCR2-
CCR5 and CCR2-CXCR4 heteromers that have been described by
a number of studies (Mellado et al., 2001; Rodríguez-Frade et al.,
2004; El-Asmar et al., 2005; Percherancier et al., 2005; Springael
et al., 2006; Sohy et al., 2007, 2009) have recently been proﬁled in
terms of dose–response curves, kinetics and Z ′ data using GPCR-
HIT (See et al., 2011). Of particular note were the ﬁndings with
the combination of CXCR4/Rluc8, β-arrestin2/Venus and CCR2.
Treatment with CXCL12 (CXCR4 agonist) resulted in a relatively
transient BRET signal that returned to baseline before 40 min,
whereas addition of CCL2 (CCR2 agonist) resulted in a more
prolonged BRET kinetic proﬁle, indicative of CCR2 forming a
complex with CXCR4. Intriguingly, treatment with a combination
of CXCL12 and CCL2 resulted in a prolonged and substantially
higher BRET signal than observed with either agonist alone. Pos-
sible explanations for this include β-arrestin2 recruitment being
facilitated by both types of receptor complex being in active recep-
tor conformations, or proximity of the donor and acceptor being
sufﬁciently close to enable detection of changes in donor–acceptor
distance and/or relative orientation. Either way, this observa-
tion provides good evidence for speciﬁc reporting of β-arrestin2
recruitment to the heteromer complex (See et al., 2011).
When generating dose–response curves with Receptor-HIT
data, the Hill slope has been seen to alter for particular combina-
tions depending upon whether the tagged or untagged receptor
is activated, consistent with stabilization of distinct complex
conformations with the different ligands. For example, with
the CCR5/Rluc8, β-arrestin2/Venus and CCR2 combination, the
dose–response curvewithCCL2was signiﬁcantly steeper thanwith
CCL4 (CCR5 agonist; See et al., 2011). As discussed previously,
the reason for this difference is currently unclear, however, as the
protein expression proﬁle is identical in both cases and the only
difference is the agonist treatment, this observation may help to
shed light on the mechanism of GPCR heteromerization and/or
allosterism across the complex in the future (See et al., 2011).
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Receptor-HIT (in the formof GPCR-HIT) has also been used to
investigate the heteromer between the angiotensin II (AngII) type
1 receptor (AT1R) and the AngII type 2 receptor (AT2R; Porrello
et al., 2011). A number of studies have shown that the AT2R does
not couple to arrestins and does not internalize following treat-
ment with AngII (Pucell et al., 1991; Hunyady et al., 1994; Turu
et al., 2006). Our BRET data indicating a lack of β-arrestin2/Rluc8
recruitment to AT2R/Venus are also consistent with these ﬁndings
(Porrello et al., 2011). Therefore, upon co-expression of untagged
AT1R with β-arrestin2/Rluc8 and AT2R/Venus, even though AngII
can bind to both receptors, the ligand is still selective in terms of
recruiting β-arrestin2 to only the untagged receptor. Therefore,
the observation that a ligand-induced BRET signal results upon
addition of AngII is indicative of AT1R-AT2R heteromerization
(Porrello et al., 2011).
Receptor-HIT on the BRET platform has recently been used to
characterize the novel heteromer between the α1A-adrenoceptor
(α1AAR) and the CXC chemokine receptor 2 (CXCR2) that
may play a role in prostate stroma (Mustafa et al., 2012). The
Receptor-HIT studies showed that the heteromer recruits β-
arrestin2 in a norepinephrine (NE)-dependent manner that can
be blocked by both the α1AR antagonist Terazosin and the
CXCR2-speciﬁc allosteric inverse agonist SB265610 (Figure 2).
This is despite the very weak β-arrestin2 interaction with α1AAR
monomers/homomers in transfected human embryonic kidney
293 cells (Stanasila et al., 2008), but consistent with the observa-
tion of α1AAR recruiting β-arrestin2 in prostate stroma (Hen-
nenberg et al., 2011). The speciﬁcity of this change in α1AAR
pharmacology with co-expression of CXCR2 was demonstrated
by the lack of effect upon co-expression of CC chemokine
receptor 2, vasopressin receptor 2 (V2R), or orexin receptor 1
(Mustafa et al., 2012).
The ligand-dependent nature of Receptor-HIT enables it
to report on, albeit without differentiating between, constitu-
tive and dynamic heteromers (Mustafa and Pﬂeger, 2011). The
α1AAR-CXCR2 complex is an example of a constitutive het-
eromer that exhibits novel pharmacology revealed by the ligand
dependency of Receptor-HIT (Mustafa et al., 2012). Indeed, BRET
FIGURE 2 | Use ofTerazosin (α1AR antagonist) and SB265610
(CXCR2 inverse agonist) to interrogate β-arrestin2 recruitment to
the α1AAR-CXCR2 heteromer. Extended BRET kinetic proﬁles were
generated for the CXCR2/Rluc8, β-arrestin2/Venus and α1AAR combination
in HEK293FT cells by treating with CXCL8 or vehicle (A) or NE or vehicle
(B) ∼30 min before a second treatment with vehicle, 10 μMTerazosin,
and/or 10 μM SB265610. Data are representative of three independent
experiments. This research was originally published in Mustafa et al. (2012).
Copyright © 2012 the American Society for Biochemistry and Molecular
Biology.
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saturation assays indicated strong speciﬁc BRET signals between
α1AAR/Rluc8 and both CXCR2/Venus and V2R/Venus, however,
the functional change in α1AAR pharmacology revealed by GPCR-
HIT was only observed with CXCR2 and not with V2R. This
indicates that proximity between GPCRs does not necessarily
result in a functional effect of one receptor on another, and fur-
ther demonstrates the ability of Receptor-HIT to unmask speciﬁc
heteromer functionality (Mustafa et al., 2012).
Receptor-HIT is also able to investigate the functionality of
apparent dynamic receptor interactions, even though it is unable
to determine the dynamics per se. This is seen for the heteromer
between the glucagon-like peptide-1 receptor (GLP-1R) and the
gastric inhibitory polypeptide receptor (GIPR; Schelshorn et al.,
2012). Using the combination of GLP-1R-Rluc8 and YPet-β-
arrestin2 in the absence and presence of GIPR, dose–response data
were generated indicating that expression of GIPR partially inhib-
ited GLP-1-induced recruitment of YPet-β-arrestin2 proximal to
GLP-1R-Rluc8. This inhibition was overcome by co-treatment
with GIP (Schelshorn et al., 2012). The authors of this study
suggested a model to explain their GPCR-HIT data, whereby for-
mation of the heteromer occurs as a consequence of low afﬁnity
binding of GLP-1 to the GIPR in addition to the GLP-1R. The
heteromer is proposed to recruit β-arrestin2 less well in compar-
ison with the GLP-1R monomer/homomer. Co-treatment with
GIP is therefore suggested to compete off the GLP-1 from GIPR,
resulting in the heteromer being dissolved and allowing improved
GLP-1-induced recruitment of β-arrestin2 to GLP-1R (Schelshorn
et al., 2012).
Receptor heteromers are complexes with unique pharmacology
that are likely to be expressed in a distinct tissue-speciﬁc manner.
This makes them exciting new prospects as drug targets, with the
goal of developing drugs with improved selectivity and reduced
side effects. Indeed, the concept of biased signaling is now well
established and applies as readily to receptor heteromers as it
does to monomers/homomers (Mustafa et al., 2010). Therefore,
heteromerization provides enormous opportunities for identi-
fying ligands with heteromer-selective and/or heteromer-biased
pharmacology, such as that observed with Labetalol acting at the
α1AAR-CXCR2 heteromer (Mustafa et al., 2012).
Screening is an essential step in the identiﬁcation of lead com-
pounds, and consequently there is a need to develop heteromer
assays that are compatible with this process. An assay’s suitability
for screening can be gauged by its Z ′ value; Z ′ values>0.5 indicate
assays that are highly suitable (Zhang et al., 1999). The potential of
Receptor-HIT as a screening assay has been demonstrated with the
CCR2-CCR5 and CCR2-CXCR4 chemokine receptor heteromers
for which a Z ′ value of 0.68 was generated with both combinations
(See et al., 2011). The Z ′ value for the α1AAR-CXCR2 heteromer
(Mustafa et al., 2012) was 0.87 (See and Pﬂeger, unpublished
observations). Unlike proﬁling, screening with Receptor-HIT is
a two-step process. Using BRET for example, compounds are
ﬁrstly screened with the Receptor-HIT conﬁguration of Receptor
A-Rluc, Receptor B and Protein C-YFP (Figure 1). This may gen-
erate hits for ligands that bind to Receptor A, Receptor B (when
in a heteromer) or the heteromer speciﬁcally. These hits are then
rescreened in parallel with the conﬁgurations Receptor A-Rluc
with Protein C-YFP, and Receptor B-Rluc with Protein C-YFP.
This will then enable differentiation between ligands that bind
to Receptor A directly, ligands that bind to Receptor B directly,
and those that are heteromer-selective (revealed by a lack of signal
in the latter two assay conﬁgurations). Furthermore, the genera-
tion of dose-response curves for the different conﬁgurations can
enable shifts in potency as well as efﬁcacy to be evaluated. Com-
parison of different signaling pathways can also reveal compounds
exhibiting biased signaling as a consequence of heteromerization
(Mustafa et al., 2012).
Finally, the amenability of Receptor-HIT for identifying het-
eromers or proﬁling/screening compounds is dependent upon
the existence of a suitable “Protein C” for a particular receptor-
receptor combination (Figure 1). For example, β-arrestin2 is a
particularly good interacting partner for most GPCRs, and when
it is not, G protein can often be utilized instead. It is also impor-
tant not to make assumptions in terms of Protein C selection,
as heteromerization can change the pharmacological proﬁle in a
manner that changes interactions with Protein C. This is illus-
trated by the ﬁndings with the α1AAR and the distinct β-arrestin2
recruitment proﬁle when forming the α1AAR-CXCR2 heteromer
(Mustafa et al., 2012).
CONCLUDING REMARKS
The formation of receptor complexes has a signiﬁcant impact on
cellular signaling. Receptor heteromers are of particular inter-
est due to the unique biochemical proﬁle they attain through
heteromerization. Characterization of a heteromer’s biochem-
ical ﬁngerprint in heterologous expression systems is the ﬁrst
step to identifying the function of the heteromer in native tissue.
Receptor-HIT is a novel cell-based approach for identifying and
proﬁling heteromers that provides information on ligand-induced
functional responses speciﬁc to the heteromer. The approach is
highly versatile, allowing for simple and yet robust heteromer
characterization. Utilizing a platform such as BRET, Receptor-
HIT is a powerful tool that enables a deeper understanding of
the molecular and physiological relevance of heteromers to be
revealed.
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